Uncategorized

Haemonetics Announces Definitive Agreement to Acquire Attune Medical

Haemonetics Corporation announced that it has entered into a definitive agreement to acquire privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device, the only FDA-cleared temperature regulation device indicated for esophageal protection during radiofrequency cardiac ablation procedures.

Haemonetics Announces Definitive Agreement to Acquire Attune Medical Read More »

Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, announced the data from a successful Phase Ib/IIa trial for lead candidate EXN407.

Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema Read More »

bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease

bit.bio, the company coding human cells for novel cures, announces the first project within a multi-year collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research to prioritise the development and delivery of a range of human cell products relevant to Parkinson’s disease.

bit.bio Announces First Project Within Multi-Year Collaboration Agreement with The Michael J. Fox Foundation (MJFF) to Generate Human Cell Products for Research and Drug Discovery in Parkinson’s disease Read More »

Scroll to Top